Market Data
Market Cap₹2,268.54 Cr.
52W High₹1,181
Current Price₹1,099.3
52W Low₹699.35
Down from 52W High6.9 %
Face Value₹5
Performance
ROCE15.03 %
ROE11.44 %
EPS (TTM)₹7.58
EPS Prev Qtr₹7.12
EPS Last Year₹8.43
EBITDA Qtr₹17.29 Cr.
Book Value₹281
Financial Health
Debt/Equity0.05
Debt/Profit0.45
Total Assets₹907.348 Cr.
Dividend Yield0.57 %
Promoter Holding63.31 %
Earning Power8.16 %
Valuation
Stock P/E34.78
Industry P/E33.81
Price to Book3.91
Price to Sales2.51
Graham Number₹447.17
Key Metrics
Face Value
₹5
About Windlas Biotech Ltd
Healthcare · Pharmaceuticals
Windlas Biotech Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹5. Market cap ₹2,268.54 Cr.
Price Chart
Strengths & Weaknesses
Strengths
- The company has a manageable debt-to-equity ratio of 0.05, indicating low financial risk.
- The ROCE of 15.03% shows efficient use of capital employed.
- The ROE of 11.44% reflects solid returns generated on shareholders' equity.
- The promoter holding stands at 63.31%, indicating strong control and alignment of interests.
Weaknesses
- The P/E ratio of 31.09 suggests that the stock may be overvalued relative to its earnings.
- The P/B ratio of 3.49 indicates that the market values the company at a premium over its book value.
- The dividend yield of 0.64% is relatively low, offering limited income to investors.
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.51 | ₹4,41,477.63 Cr | 0.87% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 86.48 | ₹2,53,031.38 Cr | 0.31% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 77.67 | ₹1,85,216.32 Cr | 0.78% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 27.01 | ₹1,20,897.46 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.28 | ₹1,12,201.64 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 99.31 | ₹1,08,698.22 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Dr Reddys Laboratories Ltd | - | 31.6 | ₹1,02,039.12 Cr | 0.65% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Mankind Pharma Ltd | - | 49.29 | ₹1,00,752.43 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Aurobindo Pharma Ltd | - | 26.56 | ₹97,814.24 Cr | 0.24% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.64 | ₹94,274.49 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 36.67 | ₹65,922.11 Cr | 0.11% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 28.65 | ₹61,804.34 Cr | 1.03% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 110.29 | ₹61,113.53 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.22 | ₹56,860.69 Cr | 1.78% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 46.73 | ₹49,091.33 Cr | 1.97% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ipca Laboratories Ltd | - | 36.13 | ₹48,712.48 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 83.03 | ₹47,949.68 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Gland Pharma Ltd | - | 42.26 | ₹47,764.08 Cr | 0.69% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ajanta Pharma Ltd | - | 38.87 | ₹44,109.77 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|
| Sales | 210.09 | 222.4 | 233.1 | 238.5 |
| ↳ QoQ Growth | - | +5.9% | +4.8% | +2.3% |
| Expenses | 191.01 | 201.44 | 216.42 | 221.21 |
| Operating Profit | 19.08 | 20.96 | 16.68 | 17.29 |
| OPM % | 9.08% | 9.42% | 7.16% | 7.25% |
| Other Income | 5.24 | 3.65 | 4.57 | 4.35 |
| Interest | 1.06 | 1.02 | 1.28 | 1.48 |
| Depreciation | 7.45 | 7.6 | 7.7 | 8 |
| EBITDA | 26.53 | 28.56 | 24.38 | 25.29 |
| EBITDA Margin % | 12.63% | 12.84% | 10.46% | 10.6% |
| Profit Before Tax | 23.26 | 23.59 | 19.97 | 20.16 |
| Tax % | 24.03% | 24.54% | 24.89% | 20.68% |
| Net Profit | 17.66 | 17.8 | 15 | 15.99 |
| ↳ QoQ Growth | - | +0.8% | -15.7% | +6.6% |
| EPS | 8.43 | 8.48 | 7.12 | 7.58 |
Profit & Loss
| Mar 2026 | TTM | |
|---|---|---|
| Sales | 904.09 | 904.09 |
| Expenses | 830.08 | 830.08 |
| Operating Profit | 74.01 | 74.01 |
| OPM % | 8.19% | 8.19% |
| Other Income | 17.81 | 17.81 |
| Interest | 4.84 | 4.84 |
| Depreciation | 30.75 | 30.75 |
| Profit Before Tax | 86.98 | 86.98 |
| Tax % | 23.59% | 23.59% |
| Net Profit | 66.45 | 66.45 |
| EPS | 31.61 | 31.61 |
Compounded Sales Growth
10Y
-
5Y
-
3Y
-
TTM
-
Compounded Profit Growth
10Y
-
5Y
-
3Y
-
TTM
-
Stock Price CAGR
10Y
-
5Y
-
3Y
-
1Y
21%
Return on Equity
10Y
-
5Y
-
3Y
-
Last Year
11.44%
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 10.48 | 10.553 |
| Reserves | 495.29 | 570.285 |
| Borrowings | 32.6 | 29.88 |
| Other Liabilities | 222.08 | 296.63 |
| Total Liabilities | 760.45 | 907.348 |
| Fixed Assets | 218.73 | 216.762 |
| CWIP | 3.2 | 56.155 |
| Investments | 223.37 | 268.37 |
| Other Assets | 315.15 | 366.06 |
| Total Assets | 760.45 | 907.348 |
Cash Flows
| Mar 2026 | |
|---|---|
| Cash from Operating Activity | 104.934 |
| Cash from Investing Activity | -91.791 |
| Cash from Financing Activity | -13.032 |
| Net Cash Flow | 0.111 |
Ratios
| Mar 2026 | |
|---|---|
| Debtor Days | - |
| Inventory Days | - |
| Days Payable | - |
| Cash Conversion Cycle | - |
| Working Capital Days | 354.25 |
| ROCE % | 8.43% |
Shareholding Pattern
| Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|
| Promoters % | 61.99% | 61.9% | 63.31% |
| FIIs % | 0.93% | 0.6% | 2.04% |
| DIIs % | 11.44% | 11.81% | 9.85% |
| Public % | 21.29% | 21.24% | 20.44% |
| No. of Shareholders | 45,461 | 44,769 | 44,996 |
Major Shareholders (>1%)
- Akw Wbl Family Private Trust (through Its Trustees Ashok Vimla Trusteeship Services Private Limited)Promoter and Promoter Group40.61%
- Ashok Kumar WindlassPromoter and Promoter Group21.32%
- Icici Prudential Pharma Healthcare And Diaganostics (p.h.d) FundPublic Shareholding3.42%
- Mncl Capital Compounder Fund 2Public Shareholding1.70%
As of 2026-06-30View all shareholders →